Treatment of Vasospastic Angina
Calcium channel blockers are the first-line treatment for vasospastic angina, with high doses often required (up to 480 mg/day verapamil, 260 mg/day diltiazem, or 120 mg/day nifedipine), combined with long-acting nitrates when monotherapy fails to control symptoms. 1
Essential Non-Pharmacologic Measures
- Smoking cessation is mandatory - smoking directly exacerbates coronary vasospasm 1, 2
- Remove other precipitating factors (emotional stress, cold exposure, hyperventilation)
Pharmacologic Treatment Algorithm
Acute Symptom Relief
- Short-acting sublingual nitroglycerin for acute episodes - highly effective in abolishing acute vasospasm 1
- Provide appropriate instructions on use for both acute relief and situational prophylaxis
First-Line Chronic Therapy
Start with a calcium channel blocker at moderate-to-high doses 1, 2, 1:
- Verapamil 240-480 mg/day
- Diltiazem 180-360 mg/day
- Nifedipine 60-120 mg/day
Key point: All calcium channel blockers prevent spasm in approximately 90% of patients 3, but achieve complete symptom resolution in only 38% 1
Second-Line: Combination Therapy
If calcium channel blocker monotherapy is insufficient, add long-acting nitrates 1, 2:
- Most patients require combination therapy with long-acting nitrates plus high-dose calcium channel blockers for symptom improvement
- Use intermittent nitrate administration to prevent tolerance 3
Refractory Cases
For patients unresponsive to standard combination therapy 1, 2:
- Consider adding a second calcium channel blocker from a different class (e.g., dihydropyridine with verapamil or diltiazem)
- Alpha-receptor blockers may provide occasional benefit
- Nicorandil (potassium channel activator) can be useful in selected refractory patients
Critical Contraindications
Beta-blockers are contraindicated in vasospastic angina 3 - they can precipitate spasm by leaving α-mediated vasoconstriction unopposed by β-mediated vasodilation
Diagnostic Confirmation
Before initiating treatment, confirm diagnosis with 4, 2:
- Documentation of transient ST-segment elevation during chest pain that resolves with nitroglycerin
- Coronary angiography to assess for obstructive disease
- Consider provocative testing with acetylcholine or ergonovine during angiography if diagnosis uncertain (avoid in patients with high-grade obstructive lesions)
Treatment Duration and Follow-up
Spontaneous remission occurs in approximately 50% of patients after ≥1 year of medical treatment 1. Therefore:
- It is acceptable to taper and discontinue treatment 6-12 months after angina has completely disappeared
- Reassess symptoms regularly during this period
Additional Considerations
- If vasospasm occurs with significant underlying coronary disease, also implement guideline-directed medical therapy for atherosclerotic disease (statins, antiplatelet therapy, ACE inhibitors) 1
- Aspirin use is controversial in pure vasospastic angina without atherosclerosis 1
- Patients with very active disease may require unusually high calcium channel blocker doses (up to 960 mg/day diltiazem) 5
Common Pitfalls to Avoid
- Do not use beta-blockers - this is the most critical error that can worsen vasospasm
- Do not use short-acting dihydropyridines alone without heart rate control
- Do not forget nitrate-free intervals when using long-acting nitrates to prevent tolerance
- Do not assume exercise testing is diagnostic - vasospastic angina is a supply problem, not demand-induced, making standard stress testing unreliable 6